Overview

Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer

Status:
Recruiting
Trial end date:
2027-02-02
Target enrollment:
Participant gender:
Summary
This is a prospective, open, randomized phase II trial.
Phase:
Phase 2
Details
Lead Sponsor:
Regina Elena Cancer Institute
Treatments:
Triptorelin Pamoate